Section Review—Oncologic, Endocrine & Metabolic: Haematopoietic Growth Factors in Cancer Chemotherapy

References

• BARTLEY TD, BOGENI3ERGER J, HUNT P, ET AL.: Identifi-cation and cloning of a megakaryocyte growth factor and development factor (MGDF) which is a ligand for MPL. Cell (1994) 77,1117-1121. First report of MGDF, megakaryocyte growth and development factor.
   Google Scholar
• LOK S, KAUSHANSKY K, IIOLLY RD, ET AL.: Cloning and
   Google Scholar
• ••expression of murine thrombopoietin cDNA and stimu-lation of platelet production in vivo. Nature (1994) 369:565-568. First report of TPO, thrombopoietin.
   Google Scholar
• KAUSHANSKY K, LOK 5, HOLLY RD, ET AL.: Promotion of •megakaryocyte progenitor expansion and differentia-tion by the c-Mpl ligand thrombopoietin. Nature (1994) 369:568-571. Report of mechanism of action of thrombopoietin.
   Google Scholar
• DE SAUVAGE F.J, HASS PE, SPENCER SD. ET AL.: Stimula-tion of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature (1994) 369:533-538. Confirms role of C-mpl in regulating platelet production.
   Google Scholar
• FRIDRIK MA, GREIL R, HAUSMANINGER H, ET AL.: Value of recombinant human granulocyte-colony stimulating factor (r-metHuG-CSF) in the treatment of aggressive non-Hodgkin's lymphomas (NHL) with an intensive weekly chemotherapy schedule. An Austrian random-ized multicenter triaL Blood (1994) 84:A79.
   Google Scholar
• LARSON RA, LINKER CA, DODGE RK, ET AL.: Granulocyte-colony stimulating factor (Filgrastina: G-CSF) reduces the time to neutrophil recovery in adults with acute tymphoblastic leukemia receiving intensive remission induction chemotherapy: cancer and leukemia group B study 9111. Proc. ASCO (1994) 13:A995.
   Google Scholar
• GISSELBRECHT C, PRENTICE HG, BACIGALUPO A, ET AL.:Placebo-controlled Phase Ill trial of lenograstim in bone-marrow transplantation. Lancet (1994) 343:696–700.
   Google Scholar
• VAN IIOEF ME, BAUMANN I, LANGE C, ETAL.: Dose-esca-lating induction chemotherapy supported by lenograstim preceding high-dose consolidation che-motherapy for advanced breast cancer. Ann. Oncol (1994) 5.217–224.
   Google Scholar
• FENNELLY D, WASSERHEIT C, SCIINEIDER J, ETAL.: Simul-taneous dose-escalation anti schedule intensification of carboplatin-based chemotherapy using peripheral-blood progenitor cells and Filgrastim - a Phase-I trial. Cancer Res (1994) 54:6137–6142.
   Google Scholar
• DUNLOP DJ, FITZSIMONS EJ, MCMURRAY A, ETA!.: Fil-grastim fails to improve haematopoietic reconstitution following rnyeloablative chemotherapy and peripheral blood stem cell rescue. Br. J. Cancer (1994) 70:943–945.
   Google Scholar
• LEGROS M, FLEURY J, CUR H, ETA!.: rHu GM-CSF afterhigh dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) rescue: a unicenter randomized study of 50 patients. Blood (1994) 84:348A.
   Google Scholar
• NADEMANEE A, SNIERCINSKI I, SCHMIDT GM, ET AL.:High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprirned and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J. Clin. Oncol. (1994) 12:2176–2186.
   Google Scholar
• DEMUYNCK HMS, DELFORGE M, ZACHEE P, ETA!.: Useof different haematopoietic growth factors to mobilize peripheral blood progenitor cells (PBPC) in myeloma patients receiving identical chemotherapy. 20th Annual Meeting of the European Group for Bone Marrow Transplan-tation (1994):A37.
   Google Scholar
• AHMED T, PRETI RA, LAKE DE, ETA!.: Comparison of 2different dosages of sargramostim to mobilize periph-eral-blood progenitors. Blood (1994) 84:A106.
   Google Scholar
• OSSENKOPPELE GJJONICHOFF AR, HUIJGENS PC, ETAL.:Peripheral blood progenitors mobilised by G-CSF (fill-grastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period follow-ing high-dose melphalan in multiple myeloma. Bone Marrow Transplant. (1994) 13:37–41.
   Google Scholar
• PETTENGELL R, 'WOLL PJ, THATCHER N, DEXTER TM, TESTA NG: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J. Clin. Oncol. (1995) 13:148–156.
   PubMed Web of Science ®Google Scholar
• MCNIECE I, GLASPY J, SHPALL EJ, LEMAISTRE F, MEN-CHACA D, BRIDDELL R: CD34* cells in pheresis harvests from patients mobilized by growth factors predict en-graftment post transplantation. Blood (1994) 84:A1378.
   Google Scholar
• YAN X-Q, BRIDDELL R, HARTLEY C, STONEY G, SAMAL B,MCNIECE I: Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood (1994) 84:795–799.
   PubMed Web of Science ®Google Scholar
• GLASPYJ, MCNIECE I, LEMAISTRE F, ETAL.: Effects of stemcell factor (rhSCF) and Filgrastim (rhG-CSF) on mobili-zation of peripheral blood progenitor cells (PBPC) and on hematological recovery post-transplant: early re-sults from a Phase I/11 study. Proc. ASCO (1994) 13:A76.
   Google Scholar
• BRLDDELL R, GLASPY J, SHPALL EJ, ETAL.: Recombinant human stem cell factor (rhSCF) and filgrasthn (rhG-CSF) synergize to mobilise myeloid, erythroid and megakaryocyte progenitors in patients with breast can-cer. Br. J. Haematol. (1994) 87:A361.
   Google Scholar
• SCHMITZ N, LINCH DC, DREGER P, ETAL.: A randomized phase HI study of Filgrastim-mobilised peripheral blood progenitor cell transplantation (PBPCT) in com-parison with autologous bone marrow transplantation (AsmT) in patients with Hodgkin's Disease (HD) and non-Hodgkin's lymphoma (NHL). Blood (1994) 84:802 (Abstract). Randomised, Phase III comparison of PBPC and BMT.
   Google Scholar
• SCHWARTZBERG L, BERET R, WEAVER C, WEST W: The effect of varying durations of granulocyte-colony stimu-lating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBPC) infusion. Blood (1994) 84:A354.
   Google Scholar
• DREGER P, HAFERLACH T, ECKSTEIN V, ETA!.: G-CSF-mo-bilised peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilisation, and composition of the graft. Br,]. Haemotol. (1994) 87:609–613.
   Google Scholar
• TO L: Mobilizing and collecting blood stem cells. In:Blood Stem Cell Transplants. Gale RP, Juttner CA, Henan PR (Eds.). Cambridge University Press, Cambridge (1994):56–75.
   Google Scholar
• ARSENIEV L, TISCHER HJ, BATTMER K, ETA!.: Treatmentof poor marrow graft function with allogeneic CD34. cells immunoselected from G-CSF-mobilirded periph-eral blood progenitor cells of the marrow donor. Bone Marrow Transplant. (1994) 14:791–797.
   Google Scholar
• BENSINGER WI, WEAVER CH, APPELBAUM FR, ETA!.: Transplantation of allogeneic peripheral blood pro-genitor cells mobilized by recombinant human granu-locyte colony-stimulating factor (rh-G-CSF). Blood (1995) 85:1655–1658.
   Google Scholar
• KRBLING M, PRZPIORKA YD, HUH YO, ETA!.: Allogeneicblood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over mar-row allografts. Blood (1995) 85:1659–1665.
   Google Scholar
• SCHMITZ N, DREGER P, SUTTORP M, ETA!.: Primary transplantation of allogeneic peripheral blood progeni-tor cells mobilized by Filgrastim (G-CSF). Blood (1995) 85:1666–1672.
   Google Scholar
• GOLDMAN J: Editorial: Peripheral blood stem cells for allografting. Blood (1995) 85:1413–1415.
   PubMed Web of Science ®Google Scholar
• LANE TA, LAW P, MARUYAMA M, ETAL.: Harvesting and enrichment of hematopoietic progenitor cells mobi-lized into the peripheral-blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF - potential role in allogeneic marrow transplantation. Blood (1995) 85:275–282.
   Google Scholar
• AMERICAN SOCIETY OF CLINICAL ONCOLOGY: AmericanSociety of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evi-dence-based, clinical practice guidelines. J. Clin. Oncol. (1994) 12:2471–2508.
   PubMed Web of Science ®Google Scholar
• NICHOLS CR, FOX EP, ROTH B, WILLIAMS SD, LOEHRERPJ, EINHORN LH: Incidence of neutropenic fever in patients treated with standard-dose combination che-motherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulat-ing factor. J. Clin. Oncol. (1994) 12:1245–1250.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, OZER H, STOLLER R, ET AL. Reduction by granulocyte colony-stimulating factor of fever and neu-tropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl. J. Med. (1991) 325:164–170.
   PubMed Web of Science ®Google Scholar
• MAYORDOMOA JI, RIVERA F, DIAZ-PUENTE MT, ET AL.: Decreasing morbidity and cost of treating febrile neu-tropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. Proc. ASCO (1993) 12:A1550.
   Google Scholar
• L'YLDEGROOT CA, RICHEL DJ, RU I FEN FFH: Peripheral- blood progenitor-cell transplantation mobilized by r-metHuG-CSF (Filgrastirn) - a less costly alternative to autologous bone-marrow transplantation. Eur.J. Cancer (1994) 30:1631–1635.
   Google Scholar
• FAUCHER C, LE CORROLLER AG, BLAISE 0, ET AL : Com- parison of G-CSF primed peripheral blood progenitor cells (PBPC) and bone marrow autotransplantation. Clinical assessment and cost-effectiveness study. 20th Annual Meeting of the European Group of Bone Marrow Transplantation (1994):A296.
   Google Scholar
• AGER 5, JESTICE K, SCOTT M, ET AL.: Autologous blood progenitor cell transplantation in patients with malig-nant lymphoma: a cost comparison ABMT. 20th Annual Meeting of the European Group for Bone Marrow Transplan-tation (1994):A299.
   Google Scholar
• INOUE H, KADOYA T, KABAYA K, ET AL.: A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human in-terleukin-6. J. Lab. Clin. Med. (1994) 124:529–536.
   Google Scholar
• MACVITTIE TJ, FARESE AM, PATCIIEN ML, MYERS LA:Therapeutic effect of recombinant interleukin-6 (IL-6) alone and combined with recombinant human I1-3 in a nonhuman primate model of high-dose, sublethal radiation-induced marrow aplasia. Blood (1994) 84: 2515–2522 .
   PubMed Web of Science ®Google Scholar
• VESOLE DH, JAGANNATII S, GLENN LD, BARLOGIE B:Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent duombocytopenia. Am. J. Ikmatol. (1994) 47:203–207.
   Web of Science ®Google Scholar
• ROTH BJ, DREICER R, EINHORN LH, ET AL.: Paclitaxel inpreviously untreated, advanced transitional cell carci-noma of the urothelium: a Phase ll trial of the Eastern Cooperative Oncology Group (ECOG). Proc. ASCO (1994) 13:A704.
   Google Scholar
• HUTTER H, MOTZER R, SCE IWARTZ L, ETAL.: Phase II trialof Taxol in cisplatin-resistant germ cell tumor (GCT) patients (pts). Proc. ASCO (1994) 13:A712.
   Google Scholar
• EINHORN LH, ROTH BJ, ANSARI R, DREICER R, LOEHRERPJ: Vinblastine, ifosfamide, and gallium (VIG) combina-tion chemotherapy in urothelial carcinoma. Proc. ASCO (1994) 13:A702.
   Google Scholar